SAN CARLOS, Calif., May 11, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, a Medicare Administrative Contractor (MAC), has issued positive coverage for the Prospera donor-derived cell-free DNA (dd-cfDNA) test. Noridian also announced it is developing a generic policy for dd-cfDNA testing that will include multiple commercially available tests under one consistent policy – Prospera’s coverage will be under the new policy in the future along with others.

Natera, Inc. Logo (PRNewsFoto/Natera, Inc.)

Last week, Natera announced the early success of the ProActive study, which has already activated 18 of the top transplant centers and enrolled more than 145 patients. In addition, Natera announced strong interest in its early access program, receiving tests from 45% of

Read More At Article Source | Article Attribution